Emapalumab for sudden lung dysfunction after transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a drug called emapalumab for people who have a sudden drop in lung function after a lung transplant. The drug targets a protein that may be causing the damage, and the goal is to treat this reaction safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to be at least 10 months past your lung transplant.
- You must have a sudden drop in lung function (acute lung allograft dysfunction) along with high levels of AI2 and CXCL9 markers in your blood or lung fluid.
- You cannot have an active bacterial infection, or active CMV or EBV infection.
- You must not be pregnant or breastfeeding, and you need to be able to give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
This study follows people with serious lung disease before and after lung transplant to understand how rejection happens and what warning signs to watch for. By studying your blood, tissue samples, and imaging, researchers hope to better predict and prevent transplant rejection.
This study looks at ways to improve outcomes for people who are waiting for or have recently received a lung transplant. It aims to find better management strategies for both donors and recipients.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
Hear when a new Lung Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.